REAL-WORLD INCIDENCE AND MANAGEMENT OF OCULAR HYPERTENSION AFTER SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE INJECTION FOR MACULAR EDEMA IN NONINFECTIOUS UVEITIS

PURPOSE: To investigate the incidence of ocular hypertension (OHT) after suprachoroidal injection of triamcinolone acetonide (SCS-TA) for noninfectious uveitic macular edema. METHODS: Retrospective review of eyes undergoing SCS-TA. The primary outcome was incidence of OHT (intraocular pressure [IOP] > 24 mmHg). Secondary outcomes included incidence of IOP > 30 mmHg, IOP rise ≥10 mmHg above baseline, and treatment for OHT. RESULTS: Seventy-six eyes of 70 patients were treated with a mean of 1.71 (range 1-5) SCS-TA injections with an average follow-up of 7.6 (range 3.0-14.9) months. Nine eyes (11.8%) developed OHT, four eyes (5.3%) had IOP > 30 mmHg, and nine eyes (11.8%) had an IOP elevation of ≥ 10 mmHg above baseline at any point after their first injection. Eyes that developed OHT were treated with topical therapy (7 eyes, mean 1.9 agents, range 1-4 agents) or close observation (2 eyes). No eyes required incisional glaucoma surgery. Eyes with a history of glaucoma or OHT (7/34, 20.1%) were more likely to develop OHT versus eyes with no history (2/42, 4.8%, P = 0.03). CONCLUSION: In this real-world cohort, SCS-TA was associated with a low-incidence of OHT, consistent with clinical trial data. A history of glaucoma or OHT is a significant association for developing OHT after SCS-TA.